Biomea Fusion is trading at $0.90, up 7.71% as of 10:59 a.m. ET on October 20, 2026; no company-specific announcement explaining the gain was found, while broader biotech strength is context only, not a confirmed cause.

  • The latest company news was October 13 Phase 1 results for investigational oral GLP-1 drug BMF-650: 1.5%–3.2% mean weight reduction at Day 29 across four cohorts.
  • Sector reports cite healthcare-stock gains alongside recent biotech M&A and clinical-trial activity.